UOC
BDTX icon

UBS O'Connor’s Black Diamond Therapeutics BDTX Stock Holding History

UBS O'Connor’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-300,000
Closed -$22.5K – 444
2024
Q3 		$22.5K Buy
300,000
+253,600
+547% +$1.38M ﹤0.01% 443
2024
Q2 		$37.1K Buy
+46,400
New +$249K ﹤0.01% 459

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

UBS O'Connor's BDTX Position: Q1 2025 in Review

UBS O'Connor sold out of Black Diamond Therapeutics (BDTX) in Q1 2025, closing a stake of 104,560 shares — an estimated $224K sold.

UBS O'Connor first reported a position in BDTX in Q1 2024 and held it in 4 quarters. The position peaked at $1.42M in Q2 2024. 84 funds tracked by Wall St. Rank hold BDTX as of Q1 2025.

  • UBS O'Connor reported no remaining Black Diamond Therapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 104,560 Black Diamond Therapeutics shares in Q1 2025, an estimated $224K.
  • UBS O'Connor first reported a position in Black Diamond Therapeutics in Q1 2024 and held it in 4 quarters.
  • UBS O'Connor's Black Diamond Therapeutics position peaked at $1.42M in Q2 2024.
  • 84 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.